Technology Description
Atypical Protein Kinase-C iota (PKCi) has been implicated as an oncogene in several cancer types including non-small cell lung carcinoma, colon, pancreatic, and ovarian cancers. Mayo Clinic researchers have extensively characterized this target and have several reagents, assay systems, and animal models available for study. Multiple screening systems have been utilized to identify small molecule inhibitors of PKCi which have been tested in animal cancer models.

Stage of Development
A Phase I clinical trial has been conducted in patients with advanced non-small cell lung carcinoma using one of the identified inhibitors. Screening studies for additional inhibitors are ongoing with multiple cancer types being assessed in animal models, and a number of additional candidate small molecule inhibitors have been identified.

File Number: 2003-222, 2009-364, 2010-002 

Other Information:
Publications
Scotti ML et al. Protein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis. Cancer Res 2010;70(5):2064-74.

Regala RP et al. Atypical protein kinase C{iota] is required for bronchialveolar stem cell expansion and lung tumorigenesis. Cancer Res 2009;69(19):7603-11.

Regala RP et al. Atypical protein kinase C iota expression and aurothiomalate sensitivity in human lung cancer cells. Cancer Res 2008;68(14):5888-95.

Fields AP et al. Protein kinase C iota: human oncogene, prognostic marker and therapeutic target. Pharmacol Res 2007;55(6):487-97.

Regala RP et al. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 2005;65(19):8905-11.

Regala RP et al. Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J Biol Chem 2005;280(35):31109-15.